BioPharma Clinical Trials
Dimerix Signs Up to AU$481 Million Licensing Deal with Everest Medicines to Advance Phase 3 Kidney Disease Therapy Across Asia
Dimerix Limited (ASX: DXB), a biopharmaceutical company developing innovative therapies for rare inflammatory diseases, has entered into an exclusive licen...
June 17, 2026 | News
Lilly's Jaypirca Combination Cuts Disease Progression Risk by 45% in Relapsed CLL Phase 3 Trial
BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the...
June 16, 2026 | News
QingSong Health and Basel Medical Group Forge Strategic Alliance to Advance AI Healthcare in Southeast Asia
QingSong Health Corp (2661.HK) and Basel Medical Group Ltd announced the signing of a Memorandum of Strategic Cooperation. The two parties i...
June 15, 2026 | News
Elixiron Advances Precision Immunotherapy Strategy with Encouraging Alzheimer's Data
Elixiron Immunotherapeutics (TPEx: 7871), a clinical-stage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmun...
June 15, 2026 | News
Akeso Expands Immunology Franchise with Approval of Gumokimab for Psoriasis
Akeso, Inc. announced that the National Medical Products Administration (NMPA) of China has approved gumokimab (AK111), the company's internally-devel...
June 15, 2026 | News
Windward Bio Doses First Patients in Phase II COPD Trial of SKB378/WIN378
COPD study initiation expands SKB378/WIN378 development into a second major respiratory disease SKB378/WIN378 is currently being evaluated in the Phase ...
June 11, 2026 | News
Formation Bio Doses First Participant in Phase I Trial of Lynk’s CNS-Penetrant TYK2 Inhibitor
Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on autoimmune and inflammatory diseas...
June 12, 2026 | News
China Approves First-in-Human Trial of Antengene’s ATG-201 for Autoimmune Diseases
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, d...
June 12, 2026 | News
Harbour BioMed Secures China IND Acceptance for Novel Bispecific Cancer Therapy HBM7004
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...
June 12, 2026 | News
Dayspring Pharma's CG2001 Meets Phase II Endpoint in Male Androgenetic Alopecia Trial
Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of positiv...
June 09, 2026 | News
OriCell Advances First GPC3 CAR T Therapy Into Confirmatory Phase II Trial for Advanced Liver Cancer
OriCell Therapeutics Holdings Limited ( The "Company" or "Oricell") , announced that its proprietary GPC3-targeted autologous CAR-T therapy, Ori-C101,...
June 08, 2026 | News
Kexing Biopharm Advances GB10 Into Phase I Trial For Neovascular AMD In China
Recently, the first subject was enrolled and dosed in the Phase I clinical trial in China for GB10 Injection, an innovative ophthalmic drug independently d...
June 08, 2026 | News
Vcare PharmaTech Secures China Approval for Next Generation TRK Inhibitor Eratrectinib in NTRK Fusion Positive Solid Tumours
NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the...
June 08, 2026 | News
Correctseq Reports 15 Month Crisis Free Outcome in First Sickle Cell Disease Patient Treated With CS 206
CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for ...
June 04, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
